September 5, 2025CancersOpen Access

Immune Checkpoint Inhibitors in Sinonasal Squamous Cell Carcinoma: A Retrospective Study and Literature Review

View Full Paper

Ask AI

Bookmark

Overall response rate for patients with sinonasal squamous cell carcinoma was 43.8%, indicating a measurable treatment response.
Higher response rates were observed in patients treated with pembrolizumab, with an overall response rate of 66.7%.
Retrospective analysis of 18 patients receiving nivolumab or pembrolizumab assessed treatment effects and prognoses.
Results highlight the need for further studies to establish effective treatment strategies for this rare malignancy.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective study reports therapeutic efficacy of immune checkpoint inhibitors in SNSCC patients, suggesting potential benefits.

Terazawa et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark